ARTICLE | Clinical News
Vatiquinone regulatory update
March 24, 2014 7:00 AM UTC
Edison said FDA granted Fast Track designation to EPI-743 to treat Friedreich's ataxia. The compound is in Phase II testing for the indication, for which it has Orphan Drug designation in the U.S. EPI...